212 related articles for article (PubMed ID: 32301520)
1. Translocation domain of botulinum neurotoxin A subtype 2 potently induces entry into neuronal cells.
Kohda T; Tsukamoto K; Torii Y; Kozaki S; Mukamoto M
Microbiol Immunol; 2020 Jul; 64(7):502-511. PubMed ID: 32301520
[TBL] [Abstract][Full Text] [Related]
2. The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.
Pellett S; Bradshaw M; Tepp WH; Pier CL; Whitemarsh RCM; Chen C; Barbieri JT; Johnson EA
mBio; 2018 Mar; 9(2):. PubMed ID: 29588398
[TBL] [Abstract][Full Text] [Related]
3. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains.
Davies JR; Rees J; Liu SM; Acharya KR
J Struct Biol; 2018 May; 202(2):113-117. PubMed ID: 29288126
[TBL] [Abstract][Full Text] [Related]
4. Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6.
Moritz MS; Tepp WH; Bradshaw M; Johnson EA; Pellett S
mSphere; 2018 Oct; 3(5):. PubMed ID: 30355669
[TBL] [Abstract][Full Text] [Related]
5. Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.
Kroken AR; Blum FC; Zuverink M; Barbieri JT
Infect Immun; 2017 Jan; 85(1):. PubMed ID: 27795365
[TBL] [Abstract][Full Text] [Related]
6. Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System.
Bradshaw M; Tepp WH; Whitemarsh RC; Pellett S; Johnson EA
Appl Environ Microbiol; 2014 Dec; 80(23):7415-22. PubMed ID: 25239905
[TBL] [Abstract][Full Text] [Related]
7. Enhancing toxin-based vaccines against botulism.
Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
[TBL] [Abstract][Full Text] [Related]
8. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype.
Kull S; Schulz KM; Weisemann J; Kirchner S; Schreiber T; Bollenbach A; Dabrowski PW; Nitsche A; Kalb SR; Dorner MB; Barr JR; Rummel A; Dorner BG
PLoS One; 2015; 10(2):e0116381. PubMed ID: 25658638
[TBL] [Abstract][Full Text] [Related]
9. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics.
Wang J; Meng J; Lawrence GW; Zurawski TH; Sasse A; Bodeker MO; Gilmore MA; Fernández-Salas E; Francis J; Steward LE; Aoki KR; Dolly JO
J Biol Chem; 2008 Jun; 283(25):16993-7002. PubMed ID: 18400760
[TBL] [Abstract][Full Text] [Related]
10. Catalytic properties of botulinum neurotoxin subtypes A3 and A4.
Henkel JS; Jacobson M; Tepp W; Pier C; Johnson EA; Barbieri JT
Biochemistry; 2009 Mar; 48(11):2522-8. PubMed ID: 19256469
[TBL] [Abstract][Full Text] [Related]
11. High Yield Preparation of Functionally Active Catalytic-Translocation Domain Module of Botulinum Neurotoxin Type A That Exhibits Uniquely Different Enzyme Kinetics.
Dhaliwal HK; Thiruvanakarasu N; Kumar R; Patel K; Ambrin G; Cai S; Singh BR
Protein J; 2017 Dec; 36(6):489-501. PubMed ID: 29030733
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the catalytic properties of the botulinum neurotoxin subtypes A1 and A5.
Wang D; Krilich J; Pellett S; Baudys J; Tepp WH; Barr JR; Johnson EA; Kalb SR
Biochim Biophys Acta; 2013 Dec; 1834(12):2722-8. PubMed ID: 24096023
[TBL] [Abstract][Full Text] [Related]
13. The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions.
Ayyar BV; Aoki KR; Atassi MZ
Infect Immun; 2015 Apr; 83(4):1465-76. PubMed ID: 25624352
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E.
Baldwin MR; Tepp WH; Pier CL; Bradshaw M; Ho M; Wilson BA; Fritz RB; Johnson EA; Barbieri JT
Infect Immun; 2005 Oct; 73(10):6998-7005. PubMed ID: 16177380
[TBL] [Abstract][Full Text] [Related]
15. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
[TBL] [Abstract][Full Text] [Related]
16. Substrate cleavage and duration of action of botulinum neurotoxin type FA ("H, HA").
Pellett S; Tepp WH; Lin G; Johnson EA
Toxicon; 2018 Jun; 147():38-46. PubMed ID: 29273248
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the functional activity of botulinum neurotoxin subtype B6.
Kohda T; Nakamura K; Hosomi K; Torii Y; Kozaki S; Mukamoto M
Microbiol Immunol; 2017 Nov; 61(11):482-489. PubMed ID: 28898517
[TBL] [Abstract][Full Text] [Related]
18. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro.
Whitemarsh RC; Tepp WH; Bradshaw M; Lin G; Pier CL; Scherf JM; Johnson EA; Pellett S
Infect Immun; 2013 Oct; 81(10):3894-902. PubMed ID: 23918782
[TBL] [Abstract][Full Text] [Related]
19. A viral-fusion-peptide-like molecular switch drives membrane insertion of botulinum neurotoxin A1.
Lam KH; Guo Z; Krez N; Matsui T; Perry K; Weisemann J; Rummel A; Bowen ME; Jin R
Nat Commun; 2018 Dec; 9(1):5367. PubMed ID: 30560862
[TBL] [Abstract][Full Text] [Related]
20. Structural and biochemical characterization of the protease domain of the mosaic botulinum neurotoxin type HA.
Lam KH; Sikorra S; Weisemann J; Maatsch H; Perry K; Rummel A; Binz T; Jin R
Pathog Dis; 2018 Jun; 76(4):. PubMed ID: 29688327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
